No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CYTO Altamira Therapeutics
- 1.2100
- -0.0800-6.20%
Close Jun 14 16:00 ET
- 1.2900
- +0.0800+6.61%
Post 18:45 ET
2.71MMarket Cap-137P/E (TTM)
1.3000High1.2000Low134.13KVolume1.2500Open1.2900Pre Close167.45KTurnover6.05%Turnover RatioLossP/E (Static)2.24MShares17.200052wk High0.38P/B2.68MFloat Cap1.200052wk Low--Dividend TTM2.22MShs Float636800.0000Historical High--Div YieldTTM7.75%Amplitude1.2000Historical Low1.2480Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Altamira Therapeutics Ltd - Merged Entity Will Be Called Altamira Therapeutics AG and Continue to Serve as Core Operating Subsidiary of Company
Express News | Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss...
Express News | Altamira Therapeutics Ltd - Co Is About to Merge Two of Its Subsidiaries in Basel (Switzerland), Auris Medical AG and Altamira Therapeutics AG
Express News | Altamira Therapeutics Ltd - Streamlining Corporate Structure; Switch in Financial Reporting From Swiss Francs to US Dollars
Altamira Therapeutics Provides Business Update
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy asse
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis,
Comments
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal.
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentri...
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentri...
$Altamira Therapeutics(CYTO.US$ I'm in let's go
1
$Altamira Therapeutics(CYTO.US$
NEWS
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
NEWS
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
1
$Altamira Therapeutics(CYTO.US$
NEWS
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
NEWS
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg